(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199534 A1

(51) International Patent Classification:
C12N 15/63 (2006.01) *C12N 9/12* (2006.01)
C12N 9/22 (2006.01) *C12N 15/62* (2006.01)

(21) International Application Number:
PCT/US2025/021171

(22) International Filing Date:
24 March 2025 (24.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/569,037 22 March 2024 (22.03.2024) US
63/569,042 22 March 2024 (22.03.2024) US

(71) Applicant: **TYPEWRITER THERAPEUTICS, INC.** [US/US]; 238 Main Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **FUJIWARA, Haruhiko**; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). **HEFFNER, Garrett**; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). **ZHOU, Jun**; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). **KAMI, Azusa**; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US). **SU, Yu-Ting**; c/o Typewriter Therapeutics, Inc., 238 Main Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: **NIE, Alex, Y.** et al.; Sheppard Mullin Richter & Hampton LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NEW R2 RETROTRANSPOSONS FOR GENE WRITING



FIG. 7

(57) Abstract: The present disclosure describes numerous new R2 retrotransposons discovered from various species. These R2 retrotransposons exhibited good retrotransposition activities in human cells. These new retrotransposons, as well as engineered versions thereof, can be suitably used for targeted gene delivery.

[Continued on next page]

WO 2025/199534 A1

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*